PlainRecalls
FDA Drug Moderate Class II Terminated

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

Reported: March 6, 2013 Initiated: December 17, 2012 #D-168-2013

Product Description

EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA

Reason for Recall

Subpotent; bupivacaine

Details

Units Affected
324 vials
Distribution
Nationwide distribution: AZ, DC, FL, GA, MA, NJ, NY, OH, and TX.
Location
San Diego, CA

Frequently Asked Questions

What product was recalled?
EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA. Recalled by Pacira Pharmaceuticals, Inc.. Units affected: 324 vials.
Why was this product recalled?
Subpotent; bupivacaine
Which agency issued this recall?
This recall was issued by the FDA Drug on March 6, 2013. Severity: Moderate. Recall number: D-168-2013.